Click here to jump to the main content
National Drug Policy New Zealand Home.

National Drug Policy New Zealand

 
Print this   Email this

Party Pills

Public Health Initiatives and Regulation

Information relating to the review and potential classification of benzylpiperazine (BZP) and related substances.

Letter to the Associate Minister of Health (Hon Jim Anderton) from the EACD (PDF, 43 KB) (May 2007)

This letter is official advice from the Expert Advisory Committee on Drugs to the Minister reaffirming their position after their meeting in May 2007.

Analysis of Submissions: Proposal to Classify BZP and Related Substances as Class C Controlled Drugs (Apr 2007)

This report comprises a detailed database summarising key points made by submitters, alongside summaries of research papers provided with submissions. The report also provides a brief overview of the submissions, pulling out key themes and views and, where they exist, presenting commonalities within and between different groups of agencies and individuals.

Letter from Associate Minister of Health on Consultation Process (PDF, 11 KB) (Jan 2007)

This letter advises the consultation process to be undertaken following the Expert Advisory Committee on Drugs' (EACD) recommendation to classify BZP, phenylpiperazine and related substances under the Misuse of Drugs Act 1975. Please note this consultation process has been extended until 23 March 2007.

Frequently Asked Questions about BZP (Dec 2006)

These about BZP were released by Associate Minister of Health (Hon Jim Anderton) on 20 December 2006 to assist interested parties in providing a submission relating to the potential classification of BZP, phenylpiperazines and related substances.

EACD Advice to the Associate Minister of Health on Benzylpiperazine (BZP) and Related Substances (PDF, 32 KB) (Dec 2006)

This letter includes the background to recommendations by the EACD that BZP, phenylpiperazine and related substances be classified as Class C1 controlled drugs under the Misuse of Drugs Act 1975.

The Expert Advisory Committee on Drugs (EACD) Advice to the Minister on Benzylpiperazine (BZP) (PDF, 134 KB) (Apr 2004)

This paper presents evidence on the risk of harm associated with Benzylpiperazine (BZP) and similar substances. They are stimulant type substances that produce effects similar to known amphetamines and hallucinogens.



Legal | newzealand.govt.nz | Minister of Health